Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in Japanese Patients With Metastatic Gastric or GEJ Cancer
NCT01983878Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2013
- Primary completion
- Jan 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company. Started Dec 2013; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01983878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01983878.